THTX
Theratechnologies
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About THTX
Theratechnologies Inc.
A biopharmaceutical company that focused on the innovative therapies for Human Immunodeficiency Virus
2015 Peel Street, 11th Floor, Montreal, Québec, Canada H3A 1T8
--
Theratechnologies Inc. was established on October 19, 1993 under the Companies Act (Quebec) IA Division or CAQ. The company is a biopharmaceutical company focused on the development and commercialization of innovative therapies to meet unmet medical needs. The company currently has two approved products: EGRIFTA SV and Trogarzo in the US. EGRIFTA SV (tisamorelin for injection) is a new formulation of EGRIFTA, originally approved by the FDA in November 2010 and marketed in the United States in January 2011. EGRIFTA SV was approved by the FDA in November 2018, launched in 2019, and has now replaced EGRIFTA in these countries. EGRIFTA SV can be stored at room temperature in a small vial with a higher concentration and therefore a smaller dose. EGRIFTA SV is currently the only therapy approved in the United States to reduce excess abdominal fat in HIV-infected lipodystrophy patients.
Company Financials
EPS
THTX has released its 2025 Q2 earnings. EPS was reported at -0.09, versus the expected 0, missing expectations. The chart below visualizes how THTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
THTX has released its 2025 Q2 earnings report, with revenue of 17.73M, reflecting a YoY change of -19.48%, and net profit of -4.46M, showing a YoY change of -552.08%. The Sankey diagram below clearly presents THTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
